Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
Frontiers in Medicine
|
September 20, 2021
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
Michelle Le, Melissa Berman-Rosa, Feras M Ghazawi, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document
Melinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Dermatology and Therapy
|
May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Eric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Chih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Dermatology and Therapy
|
February 5, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh, et al.
The Journal of Dermatological Treatment
|
March 11, 2026
Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis
Brian S Kim, Shawn G Kwatra, Gil Yosipovitch, et al.
Dermatology and Therapy
|
June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Jonathan I Silverberg, Alan D Irvine, Peter Foley, et al.
Dermatology and Therapy
|
April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim A Papp, Jennifer Beecker, Curtis Cooper, et al.
JAMA Dermatology
|
April 19, 2023
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
Amy S Paller, Carsten Flohr, Michael Cork, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
Frontiers in Medicine
|
September 20, 2021
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
Michelle Le, Melissa Berman-Rosa, Feras M Ghazawi, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document
Melinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Dermatology and Therapy
|
May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Eric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.
Journal of Cutaneous Medicine and Surgery
|
November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Chih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Dermatology and Therapy
|
February 5, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh, et al.
The Journal of Dermatological Treatment
|
March 11, 2026
Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis
Brian S Kim, Shawn G Kwatra, Gil Yosipovitch, et al.
Dermatology and Therapy
|
June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Jonathan I Silverberg, Alan D Irvine, Peter Foley, et al.
Dermatology and Therapy
|
April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim A Papp, Jennifer Beecker, Curtis Cooper, et al.
JAMA Dermatology
|
April 19, 2023
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
Amy S Paller, Carsten Flohr, Michael Cork, et al.
Page
of 10